An optometrist-focused view of how often patients ask about pharmacologic presbyopia treatment, how frequently drops are prescribed, which patients appear most satisfied, how clinicians position them, what drives 90-day drop-off, how affordability and retinal screening influence use, and whether the category looks more likely to remain niche or expand.
Audience: Optometrists
Countries: 2
Completion Rate: 86.2%
SGID: 8957513
-Hero findings
– Quick Read — Key Findings
Presbyopia is no longer managed only with readers, progressives, contact lenses, or procedural options. The U.S. pharmacologic category has expanded from pilocarpine-based products to newer pupil-modulating approaches, including FDA approval of aceclidine in 2025 and a carbachol-brimonidine combination in 2026. That gives optometrists more ways to discuss a reversible, non-surgical option with patients who want less dependence on near correction.
FDA labeling keeps safety and counseling front and center: newer miotics warn of temporary dim or blurred vision, and some advise a retinal exam first, since rare retinal tears or detachments have been reported. So the MDForLives data is less about whether these drops can sharpen near vision in a trial and more about what happens once a real patient asks, tries a prescription, pays for it, lives with the effect day to day, and decides whether it is worth keeping.
36.0% say patients proactively ask about eye drops a few times per month, while 24.0% hear the question daily or multiple times per week.
36.0%
say patients ask about drops a few times per month
64.0%
write or dispense 1-5 prescriptions or trial doses in a typical month
Demand is real, only 8.0% say patients almost never ask, yet prescribing stays cautious: 64.0% write just one to five prescriptions or trial doses a month, 16.0% do not prescribe at all, and only 20.0% do more than five. That gap is telling, because patient curiosity gets filtered through suitability, expectations, product choice, cost, and the honest question of whether the benefit is meaningful enough to keep using.
60.0% identify early presbyopes aged 40-47 with minimal distance refractive error as the profile with the highest long-term satisfaction and success.
Post-refractive emmetropes come next at 28.0%, while moderate-to-advanced presbyopes and pseudophakic patients are chosen far less. It points to a realistic use case: people whose near demand is just emerging but whose distance vision is still good may enjoy a temporary near boost more than those chasing full spectacle independence, which is also why a drop can appeal without replacing conventional correction.
40.0% primarily position presbyopia drops as a supplemental or part-time option for social events, dining out, or active days.
Daily replacement of readers or progressives is the goal for 32.0%, while 20.0% reserve drops for patients who refuse glasses or contacts and 8.0% pair them with contact lenses. So the dominant positioning is situational, and that matters, because expectations set at the first visit shape whether a patient reads variable near performance as a failure or as a fair trade for a few hours of freedom from readers.
Pupil selectivity and dual-action combination formulations are tied as the most selected prescribing characteristic at 32.0% each.
Lower-concentration or preservative-free options follow at 20.0%, affordability at 12.0%, and rapid onset at just 4.0%. The order says a lot: speed is not the deciding factor here. Optometrists care more about the quality of miosis, duration, and tolerability, which fits a category where how the drop feels after it goes in matters more for repeat use than shaving a minute off onset.
56.0% say less than 20% of their presbyopia-drop patients are still refilling and using the treatment after 90 days.
56.0%
report that fewer than 20% of patients continue to refill and use after 90 days
48.0%
cite out-of-pocket cost or lack of insurance among the top two reasons for discontinuation
Only 4.0% land in the 61-80% continuation band. Asked for the top two reasons patients stop or skip refills, cost or lack of insurance leads at 48.0%, closely followed by too little near-vision gain at 44.0%; headache or brow ache and dimness or low-light trouble each show up for 36.0%, and ocular discomfort for 32.0%. Persistence is really a value equation: patients have to see enough benefit, live with the trade-offs, and feel the recurring cost is worth it.
68.0% require a dilated fundus examination for all patients before prescribing presbyopia drops.
That fits current FDA labeling for some newer miotics, which advises a retinal exam first because rare tears or detachments have been reported. The outlook is cautious too: 48.0% expect drops to stay a minor niche over the next three years and 40.0% expect moderate growth, while only 8.0% foresee a mainstream modality and 4.0% first-line use for most early presbyopes.
The survey describes a category that has clearly entered the optometry conversation. Patients are asking, most respondents prescribe at least occasionally, and there is a plausible best-fit group in early presbyopes with otherwise good distance vision. Yet the everyday model stays selective and situational rather than universal.
The harder problem shows up after the first prescription. Most respondents report very low 90-day refill persistence, with cost, too little near-vision gain, headache, dimness, and discomfort all pulling against continued use, while retinal screening stays a real part of the workflow and nearly half expect the category to remain niche for now. So the opportunity is not simply more trials; it is a better fit between expectation, formulation, safety, price, and real-world benefit, so a first prescription becomes a treatment patients actually choose to keep.
You have read the summary
Common questions about pharmacologic presbyopia treatment, near-vision effects, duration, side effects, spectacle independence, and retinal screening.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
